Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06077292 · ClinicalTrials.gov registry record · NA
Cannabis THC Potency, Metabolism, and Cognitive Impairment in Young Adults
A NA study of Cognitive Impairment and Cannabis Use, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- NA
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT06077292: Recruiting NA study of Cognitive Impairment and Cannabis Use, sponsored by University of California, San Francisco.
NCT06077292 is a NA study of Cognitive Impairment and Cannabis Use that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 110 participants, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06077292, a NA study of Cognitive Impairment and Cannabis Use, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this interventional study is to determine the impact of high potency THC product use on cognitive function of young adults aged 21-25. The main question it aims to answer is: will cannabis users who switch to less potent THC products demonstrate improved cognitive function compared to baseline? Other questions this study aims to answer include: * Can researchers accurately assess THC consumption among frequent cannabis users? * Can researchers effectively incentivize cannabis users to use less potent THC products? * Do genetic variations in THC metabolism impact urinary THC excretion? * Do genetic variations in THC metabolism impact cognitive performance in cannabis users? * Are quantitative urinary THC values predictive of cognitive impairment? * How can researchers use research findings to inform harm reduction practices for people who use cannabis? Participants will submit blood and urine samples and be incentivized to use less potent THC products.
Conditions Studied
Interventions
- BEHAVIORAL 15% THC Potency Reduction
- BEHAVIORAL 35% THC Potency Reduction
Study Locations (1)
California
- University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2025-03-17 |
| Est. Completion | 2026-03-14 |
| Phase | NA |
What NCT06077292 shows while recruiting
NCT06077292 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (83% lower).
The record links to 5 conditions, with Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which 15% THC Potency Reduction is the first listed.
NCT06077292 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06077292 about?
NCT06077292 is a clinical study titled "Cannabis THC Potency, Metabolism, and Cognitive Impairment in Young Adults". The goal of this interventional study is to determine the impact of high potency THC product use on cognitive function of young adults aged 21-25. The main question it aims to answer is: will cannabis users who switch to less potent THC products demonstrate improved cognitive function compared to b...
What is the current status of trial NCT06077292?
This trial is currently recruiting. It is a NA study. The enrollment target is 110 participants. The study started on 2025-03-17. Estimated completion is 2026-03-14.
What conditions does trial NCT06077292 study?
This clinical trial studies the following conditions: Cognitive Impairment, Cannabis Use, THC, Marijuana Use, THC Vaping.
What interventions are being tested in trial NCT06077292?
The interventions under investigation include: 15% THC Potency Reduction (BEHAVIORAL), 35% THC Potency Reduction (BEHAVIORAL).
Who is sponsoring clinical trial NCT06077292?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06077292 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06077292's enrollment target sits among peer trials
110 37th of 105 higher than 67 of 105 other Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS
RECRUITING · NA
-
Mind Your Heart-II
RECRUITING · NA
-
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
RECRUITING · NA
-
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
RECRUITING · NA
-
Essential Fats For Enhancing Cognitive Thinking (EFFECT) Study
RECRUITING · NA
-
Amygdala Memory Enhancement
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI